ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy

STZ-induced diabetes led to the development of early features of diabetic nephropathy. Overexpression of DDAH1 and lowering of systemic ADMA levels did not prevent these changes, indicating that ADMA is not the major mediator of the early diabetic changes reflected by this experimental model.